MNPR revenueQ2 2026$0
MNPR revenue was $0 in fiscal Q2 2026 (ended Jun 30, 2026). For the full fiscal 2025 it was $0, compared with $0 in fiscal 2024.
Monopar Therapeutics Inc. (MNPR) financials
For fiscal 2025 (ended Dec 31, 2025), Monopar Therapeutics Inc. reported $0 of revenue and -$13.72M of net income.
- Revenue, FY2025
- $0
- Net income, FY2025
- -$13.72M
- Cash
- $52.76M
- Market cap
- $479.4M
FY2016FY2025
FY2016FY2025
MNPR revenue and earnings growth
MNPR net incomeQ2 2026-$5.31M
MNPR net income was -$5.31M in fiscal Q2 2026 (ended Jun 30, 2026), compared with -$2.45M a year earlier. For the full fiscal 2025 it was -$13.72M, compared with -$15.59M in fiscal 2024.
Income statement
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | - | - | - | - | $0 | $0 | $0 | $0 |
| Research and development | $9.90M | $13.01M | $5.60M | $7.59M | $6.49M | $4.07M | $1.97M | $1.77M | $935.3K | $280.4K |
| Selling, general and admin | $6.80M | $3.16M | $3.23M | $2.95M | $2.63M | $2.44M | $2.36M | $1.56M | $1.17M | $912.5K |
| Operating income | -$16.70M | -$16.16M | -$8.83M | -$10.54M | -$9.13M | -$6.51M | -$4.32M | -$3.33M | -$16.60M | -$1.19M |
| Pre-tax income | -$13.72M | -$15.59M | -$8.40M | - | - | - | - | -$3.30M | -$16.55M | - |
| Income tax | $800 | $800 | $800 | $800 | $0 | $18.4K | $0 | -$70.8K | -$3.6K | $800 |
| Net income | -$13.72M | -$15.59M | -$8.40M | -$10.52M | -$9.10M | -$6.30M | -$4.22M | -$3.23M | -$16.55M | -$1.19M |
| EPS, basic | -$1.85 | -$4.11 | -$3.04 | -$0.83 | -$0.73 | -$0.58 | -$0.45 | -$0.35 | -$1.89 | - |
| EPS, diluted | - | - | - | - | -$0.73 | -$0.58 | -$0.45 | -$0.35 | -$1.89 | - |
| Diluted shares | - | - | - | - | 12.5M | 11.0M | 9.3M | 9.3M | 8.8M | - |
Balance sheet
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $61.83M | $45.82M | $7.27M | $8.19M | $20.30M | $16.74M | $13.21M | $6.89M | $9.78M | $2.87M |
| Current assets | $140.46M | $60.29M | $7.33M | $13.17M | $20.52M | $16.80M | $13.23M | $7.25M | $9.13M | $2.10M |
| Total assets | $140.72M | $60.29M | $7.35M | $13.23M | $20.52M | $16.87M | $13.35M | $7.32M | $9.93M | $2.90M |
| Current liabilities | $2.74M | $5.25M | $1.76M | $3.13M | $1.58M | $1.18M | $724.2K | $399.6K | $311.9K | $64.5K |
| Total liabilities | $2.89M | $5.25M | $1.76M | $3.14M | $1.58M | $1.18M | $724.2K | $399.6K | $311.9K | $64.5K |
| Shareholders' equity | $137.83M | $55.04M | $5.59M | $10.09M | $18.94M | $15.69M | $12.63M | $6.92M | $9.62M | $2.83M |
Cash flow
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$12.20M | -$6.40M | -$7.86M | -$7.23M | -$7.32M | -$4.66M | -$3.02M | -$2.68M | -$2.63M | -$1.19M |
| Investing cash flow | -$63.45M | -$14.34M | $4.93M | -$4.92M | $0 | - | - | - | - | - |
| Financing cash flow | $91.57M | $59.29M | $2.03M | $32.9K | $10.88M | $8.18M | $9.35M | -$206.3K | $9.54M | $1.26M |
| Share repurchases | $35.00M | $0 | - | - | - | - | - | - | - | - |
| Stock-based compensation | $4.84M | $1.14M | $1.90M | $1.64M | - | - | - | - | - | - |
Key ratios
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Return on equity | -10.0% | -28.3% | -150.4% | -104.2% | -48.1% | -40.2% | -33.5% | -46.7% | -172.1% | -41.9% |
| Return on assets | -9.7% | -25.9% | -114.4% | -79.5% | -44.4% | -37.4% | -31.6% | -44.1% | -166.7% | -40.9% |
| Current ratio | 51.35 | 11.47 | 4.17 | 4.21 | 12.98 | 14.28 | 18.27 | 18.15 | 29.28 | 32.48 |
Income statement
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | - | - | - | - | - | - | - | - | - | - |
| Research and development | $4.77M | $3.49M | $3.94M | $2.59M | $1.73M | $1.64M | $9.92M | $984.3K | $1.13M | $966.1K | $1.04M | $1.32M |
| Selling, general and admin | $1.88M | $1.74M | $2.21M | $1.50M | $1.50M | $1.58M | $1.15M | $590.6K | $657.8K | $757.3K | $876.4K | $749.5K |
| Operating income | -$6.64M | -$5.23M | -$6.16M | -$4.09M | -$3.23M | -$3.22M | -$11.07M | -$1.57M | -$1.79M | -$1.72M | -$1.91M | -$2.07M |
| Net income | -$5.31M | -$3.89M | -$5.20M | -$3.44M | -$2.45M | -$2.62M | -$10.93M | -$1.30M | -$1.72M | -$1.64M | -$1.81M | -$1.95M |
| EPS, basic | -$0.62 | -$0.46 | - | -$0.48 | -$0.35 | -$0.38 | - | -$0.37 | -$0.49 | -$0.51 | - | -$0.69 |
Balance sheet
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $52.76M | $52.54M | $61.83M | $127.68M | $39.50M | $39.71M | $45.82M | $6.02M | $6.12M | $7.81M | $7.27M | $5.52M |
| Current assets | $134.76M | $137.74M | $140.46M | $144.09M | $53.75M | $55.08M | $60.29M | $6.07M | $7.18M | $8.91M | $7.33M | $8.57M |
| Total assets | $134.98M | $137.98M | $140.72M | $144.20M | $53.87M | $55.09M | $60.29M | $6.07M | $7.18M | $8.91M | $7.35M | $8.59M |
| Current liabilities | $4.02M | $2.46M | $2.74M | $2.57M | $1.58M | - | $5.25M | - | - | - | $1.76M | $1.98M |
| Total liabilities | $4.12M | $2.59M | $2.89M | $2.64M | $1.66M | $1.49M | $5.25M | $1.12M | $1.09M | $1.44M | $1.76M | $1.98M |
| Shareholders' equity | $130.85M | $135.39M | $137.83M | $141.56M | $52.20M | $53.59M | $55.04M | $4.95M | $6.09M | $7.48M | $5.59M | $6.61M |
Cash flow
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$3.25M | -$3.47M | -$3.37M | -$2.09M | -$1.08M | -$5.66M | -$2.00M | -$1.07M | -$1.68M | -$1.66M | -$1.55M | -$1.94M |
| Investing cash flow | $4.12M | -$5.58M | -$62.19M | -$2.13M | $1.19M | -$325.8K | -$14.34M | $985.7K | -$2.4K | -$983.3K | $2.97M | -$13.1K |
| Financing cash flow | -$647.4K | -$200.2K | -$384.7K | $92.39M | -$316.8K | -$115.7K | $56.14M | -$16.5K | -$9.9K | $3.18M | $334.5K | $246.7K |
| Share repurchases | - | - | $0 | - | - | - | $0 | - | - | - | - | - |
| Stock-based compensation | $1.43M | $1.69M | $1.10M | $1.10M | $1.28M | $1.36M | $278.6K | $199.1K | $334.4K | $328.7K | $474.2K | $474.1K |
Key ratios
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current ratio | 33.56 | 56.04 | 51.35 | 56.10 | 33.94 | - | 11.47 | - | - | - | 4.17 | 4.32 |
Source: XBRL data Monopar Therapeutics Inc. files with the SEC, latest filing dated Aug 12, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.
* Worked out from the filings rather than stated in them: Q4 is the full year less the first nine months.
Per-share figures are as filed. The filings show no stock split in these periods.
EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.
MNPR peers
| Company | Revenue | Growth | Net income | Net margin | Market cap |
|---|---|---|---|---|---|
| MNPR | $0 | - | -$13.72M | - | $479.4M |
| LLY | $86.46B | +45.5% | $27.58B | 31.9% | $1.27T |
| JNJ | $99.33B | +7.8% | $16.09B | 16.2% | $664.95B |
| ABBV | $66.01B | +10.7% | $10.34B | 15.7% | $514.92B |
| MRK | $67.38B | +4.9% | $2.45B | 3.6% | $361.71B |
| NVS | $54.53B | +8.4% | $13.98B | 25.6% | $310.17B |
| AZN | $58.74B | +8.6% | $10.22B | 17.4% | $289.10B |
| ABT | $48.23B | +10.0% | $4.70B | 9.7% | $190.39B |
| NVO | DKK 309.06B | +6.4% | DKK 102.43B | 33.1% | $178.51B |
MNPR FAQ
5 questionsWhat is MNPR revenue?
Monopar Therapeutics Inc. (MNPR) reported $0 of revenue for fiscal 2025 (ended Dec 31, 2025).Is MNPR profitable?
No. Monopar Therapeutics Inc. reported a net loss of $13.72M for fiscal 2025 (ended Dec 31, 2025).How much cash and debt does MNPR have?
Monopar Therapeutics Inc. reported $52.76M in cash and cash equivalents on its most recent balance sheet in SEC filings.When did MNPR last report financial results?
The latest statements here come from Monopar Therapeutics Inc.'s 10-Q filed on Aug 12, 2026, covering the period ended Jun 30, 2026.Where does this MNPR financial data come from?
Quantisnow builds these statements from the structured XBRL data Monopar Therapeutics Inc. files with the SEC. It is provided for information only and is not investment advice.